Experienced in Isolated Hypogonadotropic Hypogonadism

Dr. Mark Warren

Endocrinology
Physicians East PA
1006 Wh Smith Blvd, 
Greenville, NC 
Offers Telehealth
Experienced in Isolated Hypogonadotropic Hypogonadism
Physicians East PA
1006 Wh Smith Blvd, 
Greenville, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Warren is an Endocrinologist in Greenville, North Carolina. Dr. Warren is rated as an Experienced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Hypoparathyroidism, Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and Low Blood Sugar.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

PHYSICIANS EAST PA
1006 Wh Smith Blvd, Greenville, NC 27834
Other Locations
PHYSICIANS EAST PA
1850 W Arlington Blvd, Greenville, NC 27834

Additional Areas of Focus

Dr. Warren has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 21, 2025
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
Enrollment Status: Completed
Publish Date: May 01, 2020
Intervention Type: Drug
Study Phase: Phase 3
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 10 Less Clinical Trials

31 Total Publications

rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.
Journal: European journal of endocrinology
Published: May 12, 2025
Similar Doctors
Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Fiona J. Cook
Endocrinology
Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Fiona J. Cook
Endocrinology
600 Moye Blvd, Ecu Physicians Endocrinology, 
Greenville, NC 
 (0.7 miles away)
252-744-1959
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fiona Cook is an Endocrinologist in Greenville, North Carolina. Dr. Cook is rated as an Advanced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. Her top areas of expertise are Type B Insulin Resistance Syndrome, Panhypopituitarism, Hypogonadotropic Hypogonadism, and Isolated Hypogonadotropic Hypogonadism. Dr. Cook is currently accepting new patients.

Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Seth N. Braunstein
Endocrinology
Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Seth N. Braunstein
Endocrinology

Wilmington Health PLLC

1000 Brabham Ln, 
Jacksonville, NC 
 (55.3 miles away)
910-341-1540
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Seth Braunstein is an Endocrinologist in Jacksonville, North Carolina. Dr. Braunstein is rated as an Advanced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Kallmann Syndrome, and Hypogonadotropic Hypogonadism.

Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. Almond J. Drake
Endocrinology
Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. Almond J. Drake
Endocrinology

East Carolina University

2100 Stantonsburg Rd, 
Greenville, NC 
 (0.6 miles away)
252-209-3000
Languages Spoken:
English
See accepted insurances

Almond Drake is an Endocrinologist in Greenville, North Carolina. Dr. Drake is rated as a Distinguished provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Follicular Thyroid Cancer, Anaplastic Thyroid Cancer, Thyroid Cancer, and Papillary Thyroid Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Warren's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile